Svetlana Selivanova is radiochemist and subject-matter expert in radiopharmaceutical sciences. She earned her BSc in chemistry (with physics and mathematics; Prof. Natalia Essina) and MSc in chemistry (Prof. Aslan Tsivadze) from Peoples’ Friendship University of Russia, and PhD in radiopharmaceutical chemistry and radiobiology from Université de Sherbrooke (Prof. Johan van Lier, Prof. Svetlana Kudrevich). After several years of postdoctoral research at Clinical Research Centre Étienne-Le-Bel (Prof. Francois Benard) and at ETH Zurich (Prof. August Schubiger, Prof. Simon Ametamey), she was promoted as a group leader and deputy head at the Centre for Radiopharmaceutical Sciences at ETH Zurich. In 2012, she was invited by CRCHU de Sherbrooke to lead the radiopharmaceutical development of commercial-scale production of Tc-99m medical isotope by cyclotron. She was recruited by CHU de Quebec – Université Laval in 2017 to set up new cyclotron and radiopharmaceutical facility. Internationally, she is a member of several professional societies, is active as expert for the European Commission Research Executive Agency, and serves as Director and Treasurer on the SNMMI Radiopharmaceutical Sciences Council Board of Directors.
Dr. Selivanova has extensive experience in cyclotron production of medical isotopes, nuclear and radiochemistry, radiopharmacology, and development of radiopharmaceuticals at all stages from early R&D to first-in-human clinical trials and cGMP. Her research interests are multidisciplinary and encompass, at large, development and application of small-molecule radiolabelled compounds for molecular imaging, therapy, and in support of drug development. Radiolabelled compounds open fascinating opportunities for fundamental science and for clinical practice and have a range of applications in medical diagnostics, drug discovery, and assessment of therapeutic interventions. These molecules deliver information about body metabolism, receptors function or drug pharmacology and, thereby, enable in vivo study of normal and pathological biochemical processes and physiology on molecular as well as systemic level. As a member of the Oncology axis, Svetlana Selivanova is involved in several projects focused on innovative cancer theranostics and translational research.
1401, 18e rue
Pavillon Notre Dame
H308
Québec, Qc
Canada G1L 1Z4
Latest news
Data not available
Robust high-yield ~1 TBq production of cyclotron based sodium [99mTc]pertechnetate.
Journal ArticleNucl Med Biol, 60 , pp. 63-70, 2018, ISSN: 0969-8051.
Abstract | Links: 
Clinical Trial with Sodium 99mTc-Pertechnetate Produced by a Medium-Energy Cyclotron: Biodistribution and Safety Assessment in Patients with Abnormal Thyroid Function.
Journal ArticleJ Nucl Med, 58 (5), pp. 791-798, 2017, ISSN: 0161-5505.
Abstract | Links:
Accelerator-based alternatives to non-HEU production of 99Mo/99mTc
Book ChapterAgency, International Atomic Energy (Ed.): Cyclotron based production of technetium-99m (Annex II, Supporting Material : Final report of the coordinated project on Accelerator-based Alternatives to Non-HEU Production of Mo-99 /Tc-99m), pp. 31-51, Vienna, IAEA, 2017, ISBN: 978-92-0-102916-4.
Radioisotopic Purity of Sodium Pertechnetate 99mTc Produced with a Medium-Energy Cyclotron: Implications for Internal Radiation Dose, Image Quality, and Release Specifications.
Journal ArticleJ Nucl Med, 56 (10), pp. 1600-8, 2015, ISSN: 0161-5505.
Abstract | Links:
Synthesis and pharmacological evaluation of ¹¹C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging.
Journal ArticleNucl Med Biol, 42 (4), pp. 399-405, 2015, ISSN: 0969-8051.
Abstract | Links:
In vitro and in vivo evaluation of N-{2-[4-(3-Cyanopyridin-2-yl)piperazin-1-yl]ethyl}-3-[(11) C]methoxybenz-amide, a positron emission tomography (PET) radioligand for dopamine D4 receptors, in rodents.
Journal ArticleChem Biodivers, 11 (9), pp. 1298-308, 2014, ISSN: 1612-1872.
Abstract | Links:
Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
Journal ArticleNucl Med Biol, 41 (7), pp. 562-9, 2014, ISSN: 0969-8051.
Abstract | Links:
Studies towards terminal (fluoroalkyl)silanes. Investigation of diethylaminosulfur trifluoride (DAST) in exchange reactions with terminal (hydroxyalkyl)silanes
Journal ArticleJ Fluor Chem, 160 , pp. 20-28, 2014, ISSN: 0022-1139.
| Links:
Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ₂ receptors.
Journal ArticleEur J Med Chem, 69 , pp. 920-30, 2013, ISSN: 0223-5234.
Abstract | Links:
Studies toward the development of new silicon-containing building blocks for the direct (18)F-labeling of peptides.
Journal ArticleJ Med Chem, 56 (19), pp. 7552-63, 2013, ISSN: 0022-2623.
Abstract | Links: